DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
LDE225 is an investigational drug.
There have been 41 clinical trials for LDE225. The most recent clinical trial was a Phase 2 trial.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Basal Cell, and Pancreatic Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Recent Clinical Trials for LDE225
|Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Phase 1|
|Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors||Mayo Clinic||Phase 1|
|A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma||Melanoma Institute Australia||Phase 2|